Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H14Cl2N2 |
Molecular Weight | 329.223 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(Cl)=C2C(N3C=CN=C3)C4=CC=CC=C4CCC2=C1
InChI
InChIKey=MPTJIDOGFUQSQH-UHFFFAOYSA-N
InChI=1S/C18H14Cl2N2/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22/h1-4,7-11,18H,5-6H2
Molecular Formula | C18H14Cl2N2 |
Molecular Weight | 329.223 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22421664
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22421664
Eberconazole is an antifungal drug with broad antimicrobial spectrum of activity. The drug was developed and approved in Spain (Ebernet 1% cream) for the treatment of tinea. Eberconazole exerts fungicidal or fungistatic activity depending on concentration, being fungicidal at higher concentration and fungistatic at lower concentrations. Eberconazole prevents fungal growth by inhibiting ergosterol synthesis, an essential component of the fungal cytoplasmic membrane leading to structural and functional changes. It prevents the fungal ergosterol synthesis by inhibiting lanosterol 14alpha-demethylase enzyme that is responsible for the formation of 14 alpha-methylsterols (precursor of ergosterols).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Lanosterol 14-alpha demethylase Sources: https://www.ncbi.nlm.nih.gov/pubmed/22421664 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
|||
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
|||
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
Sample Use Guides
Eberconazole (Ebernet 1% cream) should be applied twice a day for 4 weeks. The cream should be applied in sufficient quantity to cover the lesion and surroundings, and should be distributed with the aid of a light massage.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14605165
Antifungal activity of eberconazole was tested against 200 strains of dermatophytes. The MIC50 values were 0.06 ug/ml (E. floccosum, M. audouinii, M. canis, M. gypseum, T. ajelloi, T. violaceum), 0.03 ug/ml (M. ferrugineum, M. fulvum, T. balcaneum), 0.25 ug/ml (T. erinacei), 0.125 ug/ml (T. interdigitale, T. mentagrophytes, T. rubrum, T. simii, T. tonsurans).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:11 GMT 2023
by
admin
on
Fri Dec 15 15:29:11 GMT 2023
|
Record UNII |
V7O1U41C9B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD01AC17
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
||
|
WHO-ATC |
D01AC17
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6680
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
100000080501
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
C118963
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
V7O1U41C9B
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
C72961
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
Eberconazole
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
978
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
72051
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL558722
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
128326-82-9
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
DTXSID90926104
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
SUB06436MIG
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
DB13656
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY | |||
|
82862
Created by
admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |